First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.

Autor: Janni W; University of Ulm, Helmholtzstraße 18, 89081, Ulm, Germany. Wolfgang.Janni@uniklinik-ulm.de., Alba E; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain., Bachelot T; Centre Léon Bérard, Lyon, France., Diab S; Rocky Mountain Cancer Centers, Aurora, CO, USA., Gil-Gil M; Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Beck TJ; Highlands Oncology Group, Fayetteville, AR, USA., Ryvo L; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Lopez R; Hospital Clínico Universitario e Instituto de Investigación Santiago-CIBERONC, A Coruña, Spain., Tsai M; Minnesota Oncology, Minneapolis, MN, USA., Esteva FJ; Perlmutter Cancer Center at New York University Langone Health, New York, NY, USA., Auñón PZ; Hospital Universitario La Paz, Madrid, Spain., Kral Z; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Ward P; Oncology Hematology Care, Kenwood, OH, USA., Richards P; Oncology Hematology Associates of Southwest Virginia, Roanoke, VA, USA., Pluard TJ; Saint Luke's Health System, Kansas City, MO, USA., Sutradhar S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Miller M; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Campone M; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2018 Jun; Vol. 169 (3), pp. 469-479. Date of Electronic Publication: 2018 Feb 05.
DOI: 10.1007/s10549-017-4658-x
Abstrakt: Purpose: The phase 3 MONALEESA-2 study demonstrated that addition of ribociclib (RIB) to letrozole (LET) significantly improved progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Here, we evaluated duration of response (DoR), tumor shrinkage, PFS by treatment-free interval (TFI), and health-related quality of life (HRQoL).
Methods: Postmenopausal women (N = 668) with HR+ , HER2- ABC and no prior systemic therapy for ABC were randomized to RIB (600 mg/day; 3 weeks on/1 week off) plus LET (2.5 mg/day; continuous) or placebo (PBO) plus LET. Primary end point was PFS; HRQoL was the secondary end point; DoR was exploratory end point and PFS by TFI was post hoc analysis.
Results: Of 501 pts with measurable disease and confirmed complete or partial response, median DoR was 26.7 months (95% CI, 24.0-NR) in the RIB arm versus 18.6 months (95% CI, 14.8-23.1) in the PBO arm. At 8 weeks, more pts in the RIB arm (32%) versus the PBO arm (17%) experienced best percentage change ≥ 60%. The average pain reduction was greater in the RIB arm (26%) versus the PBO arm (15%). PFS benefit was seen with RIB vs PBO, irrespective of TFI.
Conclusion: RIB plus LET versus PBO plus LET is associated with earlier and more durable tumor response, greater degree of tumor shrinkage and pain reduction, and PFS benefit irrespective of TFI. These data further support RIB plus LET as a first-line treatment option for postmenopausal women with HR+ , HER2- ABC.
Databáze: MEDLINE
Externí odkaz: